1-4 of 4
Herlinde Dumez
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Frederico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, Christie Low, Jerry Huang, Margaret Dugan, Kathryn Parker, Eric Walk, Allan van Oosterom, Erika Martinelli, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (22): 6364–6372.
https://doi.org/10.1158/1078-0432.CCR-12-1499
Published: 14 November 2012
View article titled, Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
Open the PDF for Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies

Ronald Hoekstra, Herlinde Dumez, Ferry A.L.M. Eskens, Ate van der Gaast, Andre S.T. Planting, Gerda de Heus, Kurt C. Sizer, Christina Ravera, Sujata Vaidyanathan, Corazon Bucana, Isaiah J. Fidler, Allan T. van Oosterom, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 6908–6915.
https://doi.org/10.1158/1078-0432.CCR-05-0720
Published: 03 October 2005
View article titled, Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacologic Study of PKI166, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Otto Soepenberg, Herlinde Dumez, Jaap Verweij, Floris A. de Jong, Maja J.A. de Jonge, José Thomas, Ferry A.L.M. Eskens, Ron H.N. van Schaik, Johan Selleslach, Judith ter Steeg, Patricia Lefebvre, Sylvie Assadourian, Ger-Jan Sanderink, Alex Sparreboom, Allan T. van Oosterom
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (4): 1504–1511.
https://doi.org/10.1158/1078-0432.CCR-04-1758
Published: 02 March 2005
View article titled, Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors
Open the PDF for Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors

Christian Dittrich, Herlinde Dumez, Hilary Calvert, Axel Hanauske, Marije Faber, Jantien Wanders, Murray Yule, Miroslav Ravic, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5195–5204.
Published: 12 November 2003
View article titled, Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of E7070, a Chloroindolyl-Sulfonamide Anticancer Agent, Administered on a Weekly Schedule to Patients with Solid Tumors in another window